论文部分内容阅读
Objective: To evaluate the efficacy and safety of irinotecan (CPT-11) plus cisplatin (DDP) in patients with small cell lung cancer (SCLC) as second-line chemotherapy. Methods: Patients received irinotecan 60 mg/m2 on days 1, 8, 15, and cisplatin 25 mg/m2 on days 1-3, every 28 days one cycle. Response was evaluated every two cycles and patients were follow-up for two years or until death. Results: Among the 28 evaluable patients, there were 1 CR, 7 PR, 8 SD and 12 PD. The response rate was 28.6% (8/28). Median time to progression (TTP) was 3.2 (0.8-5.6) months. Median survival after second-line treatment was 7.5 (1.5-31) months and overall survival was 15 (2.3-43.5) months. The most common adverse effect was hematological toxicity with 36.7% (11/30), grades III-IV neutroperia. Hepatic toxicity was another major side effect. Only one patient developed grade III diarrhea. Conclusion: The combination of irinotecan and cisplatin is feasible, effective, and safe for SCLC as second-line treatment.
Objective: To evaluate the efficacy and safety of irinotecan (CPT-11) plus cisplatin (DDP) in patients with small cell lung cancer (SCLC) as second-line chemotherapy. Methods: Patients received irinotecan 60 mg / m2 on days 1, 8 , 15, and cisplatin 25 mg / m2 on days 1-3, every 28 days one cycle. Response was evaluated every two cycles and patients were follow-up for two years or until death. Results: Among the 28 evaluable patients, there were 1 CR, 7 PR, 8 SD and 12 PD. The response rate was 28.6% (8/28). Median time to progression (TTP) was 3.2 (0.8-5.6) months. Median survival after second- 1.5-31) months and overall survival was 15 (2.3-43.5) months. The most common adverse effect was hematological toxicity with 36.7% (11/30), grades III-IV neutroperia. Hepatic toxicity was another major side effect. Only one patient developed grade III diarrhea. Conclusion: The combination of irinotecan and cisplatin is feasible, effective, and safe for SCLC as second-line treat ment.